Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fluphenazine Decanoate

FDA-approved product (injectable, injection), marketed as Fluphenazine Decanoate, Prolixin Decanoate.

Registered studies
4
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Fluphenazine Decanoate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Mental or behavioural disorder
  • Psychosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Phenothiazines with piperazine structure
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis80.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

4registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fluphenazine Decanoate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fluphenazine Decanoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum

    NCT05766007 · start 2023-08-01

    Registered record
    Registry ID
    NCT05766007
    Conditions
    Schizophrenia; Psychosis; Mania; Pregnancy; Drug Exposure in Utero; Drug Exposure Via Breast Milk; Antipsychotic Agents; Breastfeeding
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-08-01
    Completion
    2025-11-21
    Enrolment
    168

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Psychosis; Mania; Pregnancy +4 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia

    NCT01323205 · start 2011-05

    Registered record
    Registry ID
    NCT01323205
    Conditions
    Schizophrenia
    Interventions
    JNJ-40411813; JNJ-40411813; Placebo; Antipsychotic medication
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-05
    Completion
    2012-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionJNJ-40411813; JNJ-40411813; Placebo; Antipsychotic medication
    PhasePhase 2
    Registry statusCompleted

  • Fluphenazine Decanoate for Psoriasis

    NCT00356200 · start 2006-07

    Registered record
    Registry ID
    NCT00356200
    Conditions
    Psoriasis
    Interventions
    Fluphenazine Decanoate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2006-07
    Completion
    2008-09
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionFluphenazine Decanoate; Placebo
    PhasePhase 2
    Registry statusTerminated

  • CATIE- Schizophrenia Trial

    NCT00014001 · start 2000-12

    Registered record
    Registry ID
    NCT00014001
    Conditions
    Schizophrenia
    Interventions
    perphenazine; olanzapine; quetiapine; risperidone; ziprasidone; clozapine; fluphenazine decanoate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2000-12
    Completion
    2004-12
    Enrolment
    1,600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionperphenazine; olanzapine; quetiapine; risperidone +3 more
    PhasePhase 4
    Registry statusCompleted